Regulatory approval

Published by the Health Service Executive. Withdrawn

In combination with erlotinib is indicated for the first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous cell lung cancer with Epidermal Growth Factor (EGFR) activating mutations

This is written in the approval document.

Reimbursement

N/A

Citation

Bevacizumab 15mg/kg Therapy - 21 days, 2026, version number 7, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6556/215_V6a_Bevacizumab_15.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2018-11-22	Health Service Executive	Indication approved for reimbursement.